Skip to main content

Advertisement

SpringerLink
Log in

Management for Peritoneal Metastasis of Colonic Origin: Role of Cytoreductive Surgery and Perioperative Intraperitoneal Chemotherapy: A Single Institution’s Experience During Two Decades

  • Gastrointestinal Oncology
  • Published:
Annals of Surgical Oncology Aims and scope Submit manuscript

Abstract

Background

Peritoneal metastasis of colonic origin is associated with a poor prognosis. This study aimed to analyze the clinicopathologic characteristics and prognostic predictors of survival in a cohort of patients treated with cytoreductive surgery (CRS) and perioperative intraperitoneal chemotherapy (POIC) during two decades.

Methods

A retrospective study analyzed a prospectively maintained database for all patients treated for peritoneal metastasis of a colonic origin (PCC) from January 1990 to April 2015.

Results

The 318 patients in our study comprised 171 men (53.8%) and 147 women (46.2%). The mean age of the patients at presentation was 50.6 years, (range 18–86 years). Overall survival was 42.5%, median survival and follow-up time was 21.5 and 15.0 months respectively. The 3 and 5 years survival rates were respectively 35 and 25%. The median survival time was 20.6 months for the men and 23.1 months for the women (p = 0.14). The mean intraoperative peritoneal carcinomatosis index (PCI) was 15.2. The patients who had a completeness of cytoreduction (CC) score of 0 or 1 (no residual disease <0.25 mm) had a median survival time of 36.6 months compared with 18.3 months for the patients with a CC-2 score and 7.6 months for the patients with a CC-3 score (p < 0.000). The significant independent predictors of survival in the multivariate analysis were the CC score and elevated tumor makers CA153 and CA125.

Conclusion

For patients with a limited extent of peritoneal metastases, CC is the most important prognostic variable for improved survival of colon cancer patients with peritoneal metastases.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Howlader N, Noone AM, Krapcho M, et al (eds). SEER cancer statistics review, 1975–2010. National Cancer Institute, Bethesda 2013.

    Google Scholar 

  2. Minsky BD, Mies C, Rich TA, et al. Potentially curative surgery of colon cancer: patterns of failure and survival. J Clin Oncol. 1988;6:106–18.

    Article  CAS  PubMed  Google Scholar 

  3. Russell AH, Tong D, Dawson LE, et al. Adenocarcinoma of the retroperitoneal ascending and descending colon: sites of initial dissemination and clinical patterns of recurrence following surgery alone. Int J Radiat Oncol Biol Phys. 1983;9:361–5.

    Article  CAS  PubMed  Google Scholar 

  4. Jayne Fook DGS, Loi C, Seow-Choen F. Peritoneal carcinomatosis from colorectal cancer. Br J Surg. 2002;89:1545–50.

    Article  PubMed  Google Scholar 

  5. Sadeghi B, Arvieux C, Glehen O, Beaujard AC, Rivoire M, Baulieux J, et al. Peritoneal carcinomatosis from non-gynecologic malignancies: results of the EVOCAPE 1 multicentric prospective study. Cancer. 2000;88:358–63.

    Article  CAS  PubMed  Google Scholar 

  6. Loupakis F, Cremolini C, Masi G, Lonardi S, Zagonel V, Salvatore L, et al. Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer. N Engl J Med. 2014;371:1609–18.

    Article  PubMed  Google Scholar 

  7. Pietrantonio F, Cremolini C, Petrelli F, Di Bartolomeo M, Loupakis F, Maggi C, et al. First-line anti-EGFR monoclonal antibodies in panRAS wild-type metastatic colorectal cancer: a systematic review and meta-analysis. Crit Rev Oncol Hematol. 2015;96,156–66.

    Article  PubMed  Google Scholar 

  8. Franko J, Shi Q, Goldman CD, Pockage B, Nelson B, Goldberg R, et al. Treatment of colorectal peritoneal carcinomatosis with systemic chemotherapy: a pooled analysis of North Central Cancer Treatment Group phase III trials N9741 and N9841. J Clin Oncol. 2012;30:263–7.

    Article  PubMed  Google Scholar 

  9. Klaver YL, Simkens LH, Lemmens VE, Koopman M, Teerenstra S, Bleichrodt RP, et al. Outcomes of colorectal cancer patients with peritoneal carcinomatosis treated with chemotherapy with and without targeted therapy. Eur J Surg Oncol. 2012;38, 617–23.

    Article  CAS  PubMed  Google Scholar 

  10. Sugarbaker PH. An overview of peritonectomy, visceral resections, and perioperative chemotherapy for peritoneal surface malignancy. In: Sugarbaker PH (ed) Cytoreductive surgery & perioperative chemotherapy for peritoneal surface malignancy (textbook and video atlas). Cine-Med Publishing, Woodbury, CT, 2012, pp 1–30.

    Google Scholar 

  11. Sugarbaker PH. Dissection by electrocautery with a ball tip. J Surg Oncol. 1994;56:246–8.

    Article  CAS  PubMed  Google Scholar 

  12. Jacquet P, Sugarbaker PH. Current methodologies for clinical assessment of patients with peritoneal metastasis. J Exp Clin Cancer Res. 1996;15:49–58.

    Google Scholar 

  13. Mohamed F, Sugarbaker PH. Intraperitoneal taxanes. Surg Oncol Clin North Am. 2003;12:825–33.

    Article  Google Scholar 

  14. Sugarbaker PH. An instrument to provide containment of intraoperative intraperitoneal chemotherapy with optimized distribution. J Surg Oncol. 2005;92:142–6.

    Article  PubMed  Google Scholar 

  15. Elias D, Mariani A, Cloutier AS, Blot F, Goéré D, Dumont F, et al. Modified selection criteria for complete cytoreductive surgery plus HIPEC based on peritoneal cancer index and small bowel involvement for peritoneal carcinomatosis of colorectal origin. Eur J Surg Oncol. 2014a;40:1467–73.

    Article  CAS  PubMed  Google Scholar 

  16. Benizri EI, Bernard JL, Rahili A, Benchimol D, Bereder JM. Small bowel involvement is a prognostic factor in colorectal carcinomatosis treated with complete cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy. World J Surg Oncol. 2012;10:56.

    Article  PubMed  PubMed Central  Google Scholar 

  17. Blackham AU, Russell GB, Stewart JH IV, Votanopoulos K, Levine EA, Shen P. Metastatic colorectal cancer: survival comparison of hepatic resection versus cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Ann Surg Oncol. 2014;21:2667–74.

    Article  PubMed  PubMed Central  Google Scholar 

  18. Yonemura Y, Canbay E, Ishibashi H. Prognostic factors of peritoneal metastases from colorectal cancer following cytoreductive surgery and perioperative chemotherapy. Sci World J. 2013;2013:978394.

    Article  Google Scholar 

  19. Elias D, Gilly F, Boutitie F, Quenet F, Bereder JM, Masvelt B, et al. Peritoneal colorectal carcinomatosis treated with surgery and perioperative intraperitoneal chemotherapy: retrospective analysis of 523 patients from a multicentric French study. J Clin Oncol. 2010;28:63–8.

    Article  PubMed  Google Scholar 

  20. Froysnes I, Larsen S, Spasojevic M, et al. Complete cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for colorectal peritoneal metastasis in Norway: prognostic factors and oncologic outcome in a national patient cohort. J Surg Oncol. 2016. DOI:10.1002/jso.24290.

    PubMed  Google Scholar 

  21. Baratti D, Kusamura S, Pietrantonio F, et al. Progress in treatments for colorectal cancer peritoneal metastases during the years 2010–2015: a systematic review. Crit Rev Oncol Hematol. 2016;100:209–22.

    Article  PubMed  Google Scholar 

  22. Faron M, Macovei R, Goere D, et al. Linear relationship of peritoneal cancer index and survival in patients with peritoneal metastases from colorectal cancer. Ann Surg Oncol. 2016;23:114–9.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Program in Peritoneal Surface Oncology, Washington Cancer Institute, Washington, DC, USA

    Chukwuemeka Ihemelandu MD, FACS & Paul H. Sugarbaker MD, FACS, FRCS

Authors
  1. Chukwuemeka Ihemelandu MD, FACS
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Paul H. Sugarbaker MD, FACS, FRCS
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Chukwuemeka Ihemelandu MD, FACS.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Ihemelandu, C., Sugarbaker, P.H. Management for Peritoneal Metastasis of Colonic Origin: Role of Cytoreductive Surgery and Perioperative Intraperitoneal Chemotherapy: A Single Institution’s Experience During Two Decades. Ann Surg Oncol 24, 898–905 (2017). https://doi.org/10.1245/s10434-016-5698-x

Download citation

  • Received:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1245/s10434-016-5698-x

Keywords

Search

Navigation